Abitibi Royalties News Release Update on Investment Portfolio

Source:  Abitibi Royalties Inc. 

Abitibi Royalties Inc. (TSX VENTURE:RZZ) ("Abitibi Royalties" or the "Company") announces that Yamana Gold Inc. ("Yamana") has recently disclosed that its wholly owned subsidiary, Brio Gold Inc. ("Brio Gold"), has filed a preliminary prospectus with the securities regulatory authorities in each of the provinces and territories of Canada in connection with qualifying a secondary offering (the "Offering") of Brio Gold common shares held by Yamana, which will be transferred to purchasers through and subject to the exercise of purchase rights (the "Purchase Rights"). Yamana intends to distribute the Purchase Rights to its shareholders as a dividend in-kind. The Purchase Rights shall provide shareholders with an opportunity to purchase from Yamana a portion of its Brio Shares or the option of selling their Purchase Rights. Abitibi Royalties owns 3,549,695 shares in Yamana and is expected to receive Purchase Rights in connection with the Offering. Abitibi Royalties will inform its shareholders of the Company's decision to participate in the Offering or sell its Purchase Rights once more information becomes available. 

About Abitibi Royalties 
Abitibi Royalties holds a 3% NSR on the Odyssey North discovery, Jeffrey Zone and the eastern portion of the Barnat Extension, located inside the Malartic CHL property and a 2% NSR on portions of the Gouldie and Charlie zones all at the Canadian Malartic mine near Val-d'Or, Québec. In addition, the Company is building a portfolio of royalties on early stage properties near producing mines. The Company owns common shares in Yamana Gold and Agnico Eagle Mines (market value), plus cash (as of June 30, 2016) of approximately CDN$47.2 million. The Company is debt free.

Golden Valley Mines Ltd. and Rob McEwen hold approximately 49.4% and 12.3% interest in Abitibi Royalties, respectively.

Abitibi Royalties Increases Royalty Holdings in Red Lake District

Source:  Abitibi Royalties Inc. 

Royalties acquired near Goldcorp's Red Lake mine & Pure Gold's Madsen mine

Abitibi Royalties Inc. (TSX VENTURE:RZZ) ("Abitibi Royalties" or the "Company") is pleased to announce that the Company has partnered with AuRico Metals Inc. ("AuRico") for the purpose of entering into an agreement with Frontline Gold Corporation ("Frontline") that allows each company to acquire a 1% net smelter royalty ("NSR") on several early stage exploration projects in the Red Lake district. The exploration projects are located south of Goldcorp's Red Lake mine, with the largest claim package adjoining Pure Gold's Madsen mine to the east and south (Fig. 1 - Claim Map). 
 
These acquisitions will build on the Company's Red Lake royalty portfolio, which also includes a 2% NSR on the White Horse Island Project (also owned by Frontline), situated between the Goldcorp / Premier Gold Rahill-Bonanza Gold Property and Premier Gold's Hasaga Gold Property (Fig. 1). A total of fourteen royalties have now been purchased near existing mines since the Company's "Royalty Search" was launched in June 2015 (http://www.abitibiroyalties.com). Please click here for a full list.

1% NSR - RED LAKE EXPLORATION PROJECTS
In exchange for the 1% NSR on the Red Lake exploration projects, Abitibi Royalties has agreed to pay Frontline Cdn$13,000, with AuRico agreeing to pay an equal amount. Abitibi Royalties will pay the cash consideration from its treasury.

Since launching the Royalty Search in June 2015, fourteen royalties near existing mining operations have been acquired, which include royalties surrounding or near Agnico Eagle and Yamana's Canadian Malartic mine in Québec, Agnico Eagle's Lapa mine in Québec, Alamos Gold's Young-Davidson mine in Ontario, Eldorado's Efemcukuru mine in Turkey, Goldcorp's Red Lake mine in Ontario, Hudbay's 777 mine in Manitoba, Metanor Resources Bachelor mine in Québec and New Gold's Rainy River mine in Ontario.

The Royalty Search (www.abitibiroyalties.com) is an easy to use website that allows mining companies and prospectors a quick way of accessing capital.
Abitibi Royalties is offering to pay the annual claim fees/taxes related to:
1) Existing mineral properties or
2) Staking of new mineral properties
In return for paying these fees, Abitibi Royalties would be granted an NSR on the property. To date over 100 properties have been submitted through the website and 14 agreements have been finalized.

MENDERES GOLD PROJECT - TURKEY (3% NSR)
The Company has been informed by Frontline that drilling initially scheduled for September / October has been deferred to the first half of 2017 in order to complete additional work that should allow Frontline to better target possible extensions of Eldorado Gold Corporation's Efemcukuru gold mine in Turkey.

YAMANA RIGHTS OFFERING
The Company has decided to sell its purchase rights ("Purchase Rights") payable by Yamana Gold and not participate in the Brio Gold offering. Abitibi Royalties intends to use the proceeds from the sale to repurchase shares of the Company under its Normal Course Issuer Bid ("NCIB"). Based on the last trading price of the Purchase Rights (Cdn$0.295), the Company would receive approximately Cdn$65,450.

About Abitibi Royalties
Abitibi Royalties holds a 3% NSR on the Odyssey North discovery, Jeffrey Zone and the eastern portion of the Barnat Extension, located inside the Malartic CHL property and a 2% NSR on portions of the Gouldie and Charlie zones, all at the Canadian Malartic mine near Val-d'Or, Québec. In addition, the Company is building a portfolio of royalties on early stage properties near producing mines. The Company owns common shares in Yamana Gold and Agnico Eagle Mines (market value), plus cash (as of September 30, 2016) of Cdn$41.8 million. The Company is debt free.

Golden Valley Mines Ltd. and Rob McEwen hold approximately 49.4% and 12.3% interest in Abitibi Royalties, respectively.
 

Abitibi Royalties Update on Royalties at Canadian Malartic Mine

Source:  Abitibi Royalties Inc

Abitibi Royalties Inc. (TSX VENTURE:RZZ) ("Abitibi Royalties" or the "Company") is pleased to provide an update on the Company's net smelter royalties ("NSR") at the Canadian Malartic Mine, near Val-d'Or, Québec. 

Malartic CHL - Odyssey North Zone (3% NSR)
Abitibi Royalties holds a 3% NSR on the Odyssey North Zone located within the Malartic CHL Property. Odyssey North is proximate to the Odyssey South Zone and together, these zones comprise the "Odyssey Zones", "Odyssey deposit", "Odyssey" or "deposits" that is east of the main Canadian Malartic Mine open pit. The Canadian Malartic Mine and Malartic CHL Property are jointly operated by Agnico Eagle Mines Limited ("Agnico Eagle") and Yamana Gold Inc. ("Yamana") through the Canadian Malartic General Partnership.

A) Odyssey - Exploration Update
The Company observes that during the third quarter of 2016, a total of 56 drill holes (40,019 metres) were completed at Odyssey, bringing the year-to-date total to 113 holes (89,774 metres). The Company understands that drilling at Odyssey is expected to continue through year-end with an increased budget, previously established at Cdn$13.5 million (95,000 metres of drilling). As stated by Agnico Eagle at the Denver Forum (September 20, 2016), nine drill rigs are active at the project.
Yamana stated in its Q3-2016 News Release, "Drilling during the third quarter focused on defining the margins of both deposits and adding infill holes to upgrade the potential resources to an inferred status. Drilling in the fourth quarter will continue this work and provide additional intercepts to better define potential high grade cross cutting structures. The Company is excited about the results received to date and looks forward to receiving a maiden Inferred Mineral Resource estimate in the first quarter of 2017."

Agnico Eagle stated in its Q3-2016 Conference Call, "[Odyssey] certainly was one of the reasons that both Yamana and Agnico Eagle were attracted to the opportunity of Osisko. There are two zones, Odyssey North and Odyssey South. We have traced Odyssey North Zone from 600 to 1,300 metres below surface, it's a large zone with a strike length over one kilometre".

B) Odyssey - Resource Estimate 
Abitibi Royalties has been advised that an inferred mineral resource is expected to be estimated for Odyssey North with the operators fourth quarter and year-end financial results due in February 2017. Abitibi Royalties anticipates receiving a separate annual reserve and resource estimate for the areas at the Canadian Malartic Mine where it holds a royalty sometime after the operator's fourth quarter and year-end financial results are released. Yamana stated during its Q3-2016 Conference Call that "Infill drilling of the Odyssey deposits has returned positive results" and, referring to future steps after the initial inferred resource, "Drilling will continue into Q1 or Q2 of 2017 to develop indicated resources that could form the basis of a pre-feasibility study".

C) Odyssey - Possible Production
Yamana states in its Q3-2016 News Release "This deposit (Odyssey) supports optionality for enhanced production and life of mine" and during the Denver Gold Forum Yamana indicated that Odyssey could operate between 8,000-10,000 tonnes per day (tpd). The operators have provided a range for Odyssey North's gold grade at between 1.5 to 3.0 grams per tonne (gpt), with an average grade being shown as 2 gpt (Agnico Eagle Exploration News Release July 27, 2016 and Yamana's Q2-2016 Results Conference Call Presentation July 29, 2016).

Drill Hole Data and Locations
The Company has not received all, or, in some cases any of the drill hole information since Agnico Eagle and Yamana assumed operational control of the Malartic CHL Property in March 2015. Odyssey North strikes east-southeast and dips deeply to the south, with the mineralization on the eastern portion of the discovery appearing to straddle the Malartic CHL Property boundary at depth (please refer to the Company's plan map in its corporate presentation located at www.abitibiroyalties.com). The Company has not independently verified the location of the published assay results, nor subsequent drilling at Odyssey North and the Company can make no assurances that all of the assay results released to date, nor all of the additional drilling targeting Odyssey North, are within the limits of the Malartic CHL Property where Abitibi Royalties holds a 3% NSR. Any resource estimate for Odyssey North released by the operators with their fourth quarter and year-end financial results may differ from the actual Abitibi Royalties NSR interest due to the location of the Malartic CHL Property boundary.

The Company also wishes to clarify the section numbers for two drill holes in its September 12, 2016 news release. Hole ODY16-5056 section number is 718000E (previously stated as 718800E) and hole ODY-16-5058 section number is 717800E (previously stated as 718800E).

Update on Barnat Extension and Jeffrey Deposits (3% NSR)
The Company holds a 3% NSR on the eastern portion of the Barnat Extension (Barnat East) and the Jeffrey gold deposit, both of which were included in the submitted Environmental Impact Assessment ("EIA") Project Notification Form. The formal EIA was submitted in February 2015 and is pending final approval.

Agnico Eagle states in its Q3-2016 News Release, "Following the Québec Bureau des Audiences Publiques sur l'Environnement ("BAPE") public hearings in June and July 2016, permitting of the Canadian Malartic extension project and Highway 117 deviation reached an important milestone with the issue of the BAPE report on October 5, 2016. The report concluded that the project is acceptable and provides several recommendations intended to enhance social acceptability. The next step is for the Ministère du Développement durable, de l'Environnement et de la Lutte contre les changements climatiques to review the report and present their decision to Cabinet for approval. No date for the approval has been set, but the Partnership anticipates that this may occur in the first half of 2017."
Based on current estimates, cash flow from the Jeffrey Zone in 2017 has been estimated by the Company at approximately Cdn$430,000 and for the Jeffrey and/Barnat Extension Zones in 2018 at approximately Cdn$1.85 million based on information provided by Agnico Eagle and Yamana (Abitibi Royalties News Release March 29, 2016) and a gold price of US$1,270 per ounce (1.34 CDN:USD Exchange Rate). No production details have been provided by the mine operators beyond 2018.

QUALIFIED PERSON
Glenn J. Mullan, Chairman, is the Qualified Person (as that term is defined in National Instrument 43-101 - Standards of Disclosure for Mineral Projects) who has reviewed this news release which is based on and derived from information contained in Agnico Eagle's Q3-2016 News Release (October 26, 2016), Agnico Eagle's Q3-2016 Results Conference Call (October 27, 2016), Agnico Eagle's Exploration News Release (July 27, 2016), Agnico Eagle's Denver Gold Forum Corporate Presentation Webcast (September 29, 2016), Yamana's Q3-2016 News Release (October 27, 2016), Yamana's Q3-2016 Results Conference Call (October 28, 2016), Yamana's Denver Gold Forum Corporate Presentation Webcast (September 20, 2016) and Q2-2016 Results Conference Call Presentation (July 29, 2016).

About Abitibi Royalties
Abitibi Royalties holds a 3% NSR on the Odyssey North discovery, Jeffrey Zone and the eastern portion of the Barnat Extension, located inside the Malartic CHL property and a 2% NSR on portions of the Gouldie and Charlie zones all at the Canadian Malartic mine near Val-d'Or, Québec. In addition, the Company is building a portfolio of royalties on early stage properties near producing mines. The Company owns common shares in Yamana Gold and Agnico Eagle Mines (market value), plus cash (as of June 30, 2016) of approximately Cdn$47.1 million. The Company is debt free.

Golden Valley Mines Ltd. and Rob McEwen hold approximately 49.4% and 12.3% interest in Abitibi Royalties, respectively.

Abitibi Royalties Received Final Exchange Acceptance for Normal Course Issuer Bid

Source:  Abitibi Royalties Inc. 

Abitibi Royalties Inc. (TSX VENTURE:RZZ) ("Abitibi Royalties" or the "Company") announces that it has received final acceptance from the TSX Venture Exchange ("TSX-V") to conduct the normal course issuer bid (the "2016 NCIB"), the details of which were previously announced on October 3, 2016. Under the 2016 NCIB, Abitibi Royalties may purchase for cancellation, from time to time at its discretion based on market conditions, share price, best use of available cash, among other factors, up to 566,182 of its issued and outstanding common shares (representing 5% of Abitibi Royalties' issued and outstanding common shares as of September 27, 2016). Purchases will be made on the open market through the facilities of the TSX-V, with TD Securities conducting the 2016 NCIB on behalf of Abitibi Royalties. 

Abitibi Royalties believes that the market price of its common shares does not always give full effect to the underlying value and that, accordingly, the purchase for cancellation of shares by Abitibi Royalties during these times will benefit the remaining shareholders by increasing their proportionate ownership in the Company.

The 2016 NCIB will commence on October 6, 2016, and will terminate on October 5, 2017, or such earlier time as the 2016 NCIB is completed or at the option of Abitibi Royalties. Any shares acquired by Abitibi Royalties pursuant to the 2016 NCIB will be cancelled.

About Abitibi Royalties Inc.
Abitibi Royalties holds a 3% NSR on the Odyssey North discovery, Jeffrey Zone and the eastern portion of the Barnat Extension inside the Malartic CHL property and a 2% NSR on portions of the Gouldie and Charlie zones all at the Canadian Malartic mine near Val-d'Or, Québec. In addition, the Company is building a portfolio of royalties on early stage properties near producing mines. The Company owns common shares in Yamana Gold and Agnico Eagle Mines (market value), plus cash (as of June 30, 2016) of CDN$47.0 million. The Company is debt free.

Golden Valley Mines Ltd. and Rob McEwen hold approximately 49.4% and 12.3% interest in Abitibi Royalties, respectively.

Abitibi Royalties to Extend Normal Course Issuer Bid

Source:  Abitibi Royalties Inc. 

Abitibi Royalties Inc. (TSX VENTURE:RZZ) ("Abitibi Royalties" or the "Company") announces that it intends to conduct a normal course issuer bid (the "2016 NCIB") to purchase through the facilities of the TSX Venture Exchange (the "TSX-V") up to 566,812 issued common shares of Abitibi Royalties (the "Common Shares") (representing 5% of Abitibi Royalties' issued and outstanding common shares as of September 27, 2016) over a period of twelve months commencing October 6, 2016. The NCIB is subject to final TSX-V acceptance, which has been conditionally approved. 

Under the NCIB, Common Shares may be repurchased in open market transactions on the TSX-V or by such other means as may be permitted by the TSX-V and under applicable Canadian securities laws. The price paid by Abitibi Royalties will be based on the market price at the time of purchase and not higher than the last independent trade of a board lot (board lot = 100 shares).

In accordance with TSX-V policy, purchases by Abitibi Royalties under the 2016 NCIB are limited, when aggregated with the total of all other purchases in the preceding 30 days, to a maximum of 2% of the Company's issued and outstanding shares at the time the purchases are made.

Common Shares that are purchased under the 2016 NCIB will be cancelled.
TD Securities Inc. will be conducting the 2016 NCIB on behalf of the Company.
The actual number of Common Shares which may be purchased and the timing of such purchases will be determined by Abitibi Royalties. Decisions regarding purchases will be based on market conditions, share price, best use of available cash, and other factors including other options to expand our portfolio of assets.

Abitibi Royalties has purchased to date an aggregate of 77,600 of its issued common shares through the facilities of the TSX-V under a normal course issuer bid (the "2015 NCIB") currently being conducted by the Issuer, which commenced October 6, 2015 and will end on October 5, 2016. Common shares purchased to date by the Issuer under the 2015 NCIB were purchased at an average price of CDN$3.19 per common share. The 77,600 common shares purchased to date under the 2015 NCIB have been returned to the Issuer's treasury and cancelled.

About Abitibi Royalties Inc.
Abitibi Royalties holds a 3% NSR on the Odyssey North discovery, Jeffrey Zone and the eastern portion of the Barnat Extension, located inside the Malartic CHL property and a 2% NSR on portions of the Gouldie and Charlie zones all at the Canadian Malartic mine near Val-d'Or, Québec. In addition, the Company is building a portfolio of royalties on early stage properties near producing mines. The Company owns common shares in Yamana Gold and Agnico Eagle Mines (market value), plus cash (as of June 30, 2016) of CDN$52.2 million. The Company is debt free.

Golden Valley Mines Ltd. and Rob McEwen hold approximately 49.4% and 12.3% interest in Abitibi Royalties, respectively.

Genius Brands International Kicks Off U.S. Fall Retail Launch of Its Tween Hit, SpacePOP, With the Debut of the Brand Apparel Program at Select Kohl's Stores Nationwide and Online

Source:  Genius Brands International, Inc.



SpacePOP YouTube Influencer Campaign Reaching Millions to Promote Juniors Sportswear Line From Jaya Apparel Available at Kohl's October 15, 2016; Sony Music/Legacy Recordings Also Releases the Original SpacePOP Soundtrack Across All Major Retail Distribution in Store and Online, Including Target, Toys"R"Us and Amazon.com

 Genius Brands International, Inc. ("GBI") (OTCQB: GNUS) launches the first apparel program at select Kohl's stores nationwide and online for its music-driven brand SpacePOP, a hit among tweens with approximately eight million channel views on YouTube (youtube.com/spacepopgirls) since its premiere on June 20^th.


GBI will debut on October 15^th a fashionable collection of SpacePOP sportswear from Jaya Apparel for tween girls (size 7-16) at Kohl's, including tops, bottoms, skirts and dresses. To support the launch, GBI has integrated the apparel line into the SpacePOP entertainment content, which is available on YouTube and across digital platforms -- Kabillion Girls Rule!, Toon Goggles, PopJam, BatteryPOP, Kid Genius channel on Comcast -- and the new line will be promoted in a digital marketing campaign, which features YouTube influencers such as Sophia Grace and Angelic wearing the collection.

In addition to the new apparel line, Sony Music/Legacy Recordings debuts the SpacePOP original soundtrack, Not Your Average Princesses, at major retail stores across the U.S. and online, including Target, Toys"R"Us and Amazon.com. Additionally, the first SpacePOP book (Imprint, part of Macmillan Children's Publishing Group), Not Your Average Princesses, an original middle grade novel with graphic novel inserts written by author Erin Downing and illustrated by Jen Bartel., is now available at Barnes & Noble, Toys"R"Us, Costco and Amazon.com.

"We have worked hard to create a unique entertainment experience to draw tween and teen girls to SpacePOP, bringing fun, adventure, friendship and best-in-class music from incomparable talent, and as a result, we are building the brand rapidly online, with an audience of millions across all of the platforms, and soon at retail," said Stone Newman, President of Global Consumer Products, Worldwide Content Sales & Marketing, GBI. "We now look forward to engaging our audience beyond the screen, working with Kohl's and Jaya Apparel to introduce a cool, fresh aspirational line of sportswear that has also been integrated into the entertainment content and digital marketing campaign, reaching millions of fans."

In 2017, GBI will continue to expand the licensed products program for SpacePOP with an array of new branded merchandise, including Madame Alexander Doll Company (fashion dolls and figures), KIDdesigns (youth electronics, tech accessories and electronic toys), Mad Dog Concepts (loungewear, sleepwear), Franco Manufacturing (bedding & bath textiles, accessories, room décor), Berkshire Fashions (hosiery, head wear, and cold weather accessories), FAB Starpoint (bags, backpacks, accessories), Taste Beauty (beauty and bath products), Bare Tree Media (emoticons), Canal Toys (craft and activity kits), Yowie Group, Ltd. (confections), H.E.R. Accessories (accessories) and Sony Pictures Home Entertainment (home entertainment).

SpacePOP was developed with best-in-class development and production team, including Emmy Award-nominated Steve Banks (head writer and story editor of SpongeBob SquarePants) as content writer; Han Lee (Pink Fizz, Bobby Jack) for original character designs; multiple Grammy Award-winning producer and music veteran Ron Fair (Fergie, Mary J. Blige, Black Eyed Peas, Pussycat Dolls, Christina Aguilera and more) and singer songwriter spouse Stefanie Fair (founding member of RCA's girl group Wild Orchid with Fergie) for the original SpacePOP theme music; and veteran music producer and composer John Loeffler (Kidz Bop, Pokemon) for original songs.

SpacePOP is comprised of over 100 serialized adventures featuring original music woven into a narrative that follows five teenage princesses who disguise themselves as musicians and form a band while they secretly plot to vanquish an evil Empress who is seeking to enslave the galaxy. SpacePop offers a colorful blend of music, fashion, beauty, friendship and intergalactic adventures resulting in an engaging lifestyle brand.

GBI has been supporting the launch of SpacePOP with a number of marketing initiatives, including a YouTube Influencer campaign; national promotional partnerships with Six Flags, Dippin' Dots and Camplified; promotional campaigns with Musical.ly and PopJam; and a dedicated SpacePOP site, SpacePOPGirls.com.

About Genius Brands InternationalHeadquartered in Beverly Hills, California, Genius Brands International, Inc. "GBI" (OTCQB: GNUS) is a publicly traded global brand management company that creates and licenses multimedia content. Led by award-winning creators and producers, the company distributes its content worldwide in all formats, as well as a broad range of consumer products based on its characters. In the children's media sector, GBI's portfolio features "content with a purpose" for toddlers to tweens, which provides enrichment as well as entertainment, including tween music-driven brand SpacePOP; preschool property debuting on Netflix Llama Llama; award-winning Baby Genius, re-launched with new entertainment and over 40 new products; adventure comedy Thomas Edison's Secret Lab®, available on Netflix, public broadcast stations and GBI's Kid Genius channel on Comcast's Xfinity on Demand; Warren Buffett's Secret Millionaires Club, created with and starring iconic investor Warren Buffett. The company is also co-producing an all-new adult animated series, Stan Lee's Cosmic Crusaders, with Stan Lee's Pow! Entertainment and The Hollywood Reporter. Additionally under GBI's wholly owned subsidiary, A Squared Entertainment, the company represents third-party properties, including From Frank, a humor greeting card and product line, and Celessence Technologies, the world's leading micro encapsulation company, across a broad range of categories in territories around the world. For additional information please visit www.gnusbrands.com.

Genius Brands International Teams With Disney's Lion King Director Rob Minkoff and Frozen Co-Writer Shane Morris on Preschool Adventure Series, "Rainbow Rangers"

Source:  Genius Brands International, Inc.

Global Retail Program Based on the CGI Animated Series in Development

 Global brand management company Genius Brands International, Inc. ("GBI") (OTCQB: GNUS) is partnering with Rob Minkoff, Director of Disney's Lion King, and Shane Morris, co-writer of Frozen, on the development and production of a new animated preschool series, "Rainbow Rangers." The announcement was made today by Andy Heyward, Chairman & CEO, GBI.

Featuring CGI animation, the creative team is in development on 52 x 11' episodes of "Rainbow Rangers." Minkoff will produce the series with Morris serving as producer and head writer along with his partner Tim Mansfield. Key series designs were created by Brittany Myers and Ruben Aquino, who was a supervising animator on many of the major Disney characters from Little Mermaid through to Frozen. Emmy Award-winning producer Andy Heyward will executive produce. GBI anticipates premiering a "Rainbow Rangers" special in fall 2017 with a full series launch in spring 2018. Additionally, the company is concurrently in development on a global licensing, merchandising and retail program to coincide with the series launch.

"Rainbow Rangers" follows the adventures of seven unique magical girls from the other side of the rainbow who serve as Earth's guardian to protect it from a wicked villain through teamwork, bravery, creativity and compassion.

"We are absolutely ecstatic to be working in collaboration with Rob, Shane, Tim and Ruben on developing this joyous, empowering adventure for little girls," said GBI's Chairman and CEO Andy Heyward. "The creative genius being poured into this original and powerful property is already attracting incredible interest from all sectors of the industry."

"Rainbow Rangers' is an exciting premise with fantastic characters and an incredible world," added Morris. "It's also inspirational. It's about the amazing power and strength of these seven magical girls. I truly enjoy writing stories that demonstrate girls can do anything, and when girls work together, well, anything is possible."

"With two young children at home, I've been exposed to a lot of TV animation lately and felt it was time to jump in with both feet," explained Minkoff. "Paw Patrol' and 'Octonauts' are two of my son's favorites. But my youngest is a girl, and I want her to have something that focuses on mission-based stories. So the appeal of a team of young girls protecting the planet is a bullseye and couldn't be more timely. 'Rainbow Rangers' is truly an incredible opportunity, and I'm very pleased to be working with GBI's creative team."

"We are very eager to debut the concept to potential media, licensing, and promotional partners at this year's MIP Junior," said Stone Newman, who was recently promoted to GBI's President of Global Consumer Products, Worldwide Content Sales & Marketing. "Our schedule is already fully booked, and we have no doubt 'Rainbow Rangers' will be a huge hit for us at the market."

About Genius Brands InternationalHeadquartered in Beverly Hills, California, Genius Brands International, Inc. "GBI" (OTCQB: GNUS) is a publicly traded global brand management company that creates and licenses multimedia content. Led by award-winning creators and producers, the company distributes its content worldwide in all formats, as well as a broad range of consumer products based on its characters. In the children's media sector, GBI's portfolio features "content with a purpose" for toddlers to tweens, which provides enrichment as well as entertainment, including tween music-driven brand SpacePOP; preschool property Llama Llama debuting on Netflix and starring the voice talent of Jennifer Garner; award-winning Baby Genius, re-launched with new entertainment and over 40 new products; adventure comedy Thomas Edison's Secret Lab®, available on Netflix, public broadcast stations and GBI's Kid Genius channel on Comcast's Xfinity on Demand; Warren Buffett's Secret Millionaires Club, created with and starring iconic investor Warren Buffett. The company is also co-producing an all-new adult animated series, Stan Lee's Cosmic Crusaders, with Lee's Pow! Entertainment and The Hollywood Reporter. Additionall, under GBI's wholly owned subsidiary, A Squared Entertainment, the company represents third-party properties, including From Frank, a humor greeting card and product line, and Celessence Technologies, the world's leading micro encapsulation company, across a broad range of categories in territories around the world. For additional information please visit www.gnusbrands.com.

Genius Brands International's Kid Genius Network, Available on Comcast, Launches First Branded Channel, Nancy Drew: Codes & Clues, in Partnership With HeR Interactive

Source:  Genius Brands International, Inc.

New Channel Premieres October 1st, Reaching 22 Million U.S. Households 

 Genius Brands International "GBI" (GNUS), a global content and brand management company, continues to build its Kid Genius Network, an on demand service available on Comcast's Xfinity on Demand platform reaching 22 million U.S. households, by partnering with HeR Interactive to launch its first branded channel, Nancy Drew®: Codes & Clues®, based on the new mobile game.

Premiering on the channel on October 1^st is the new animated series, Nancy Drew: Codes & Clues, featuring the smart, independent, gutsy and resourceful teen detective whose stories have been published in 22 languages with more than 100 million copies in print worldwide. In this new series, targeting girls ages 6 - 11, viewers will meet a tween version of Nancy and her best friends, Bess and George who must work together, along with their new robot puppy, to uncover clues to solve the mystery of the missing tech fair project. The series introduces younger fans to the foundational concepts of coding in a fun, engaging and accessible manner, as the de-TECH-tive team don undercover disguises, and employ coding principles to solve their clues together with critical thinking skills involving pattern recognition, problem solving and spatial visualization.

This content is based on the recently launched Nancy Drew: Codes & Clues story-driven, hidden-object mobile game from the award-winning mystery adventure game publisher and developer, HeR Interactive, developed for kids without any coding experience or skills.

In addition to launching on Kid Genius Network, Nancy Drew: Codes & Clues will be a new sponsor of GBI's hit tween YouTube series, SpacePOP, which has already amassed over 7 million channel views since its June launch.

"In keeping in line with our mission of providing 'content with a purpose,' Nancy Drew: Codes & Clues is the perfect complement to our ever-growing Kid Genius Network, and we look forward to collaborating with HeR Interactive to create this compelling destination for young girls," stated Deb Pierson, General Manager, Kid Genius Channel. "Introducing the foundational concepts of coding and problem solving to kids at a young age has become very important, and with our new channel, we are delivering that concept in an engaging and entertaining way."

"The Kid Genius Network is the ideal entertainment platform to launch the Nancy Drew Codes & Clues channel," said Penny Milliken, CEO of HeR Interactive. "In addition to the series, the branded channel will highlight our new app that has been sparking an interest in coding with early learners all over the world. Girls need to see and experience positive STEM role models in a way that matches their viewing, learning, and play patterns. What better way to introduce them to this coding super hero than through a streaming VOD platform reaching millions of fans?"

The Kid Genius Network is a free, advertising supported On Demand service, featuring GBI's innovative, original animation series, including SpacePOP, Thomas Edison's Secret Lab, Stan Lee's Mighty 7 and Warren Buffett's Secret Millionaires Club alongside award-winning Baby Genius content and such classic children's series as ABC Monsters. For more information, visit www.kidgeniustv.com
 
About Genius Brands International:
Headquartered in Beverly Hills, California, Genius Brands International, Inc. "GBI" (OTCQB: GNUS) is a publicly traded global brand management company that creates and licenses multimedia content. Led by award-winning creators and producers, the company distributes its content worldwide in all formats, as well as a broad range of consumer products based on its characters. In the children's media sector, GBI's portfolio features "content with a purpose" for toddlers to tweens, which provides enrichment as well as entertainment, including tween music-driven brand SpacePOP; preschool property debuting on Netflix Llama Llama; award-winning Baby Genius, re-launched with new entertainment and over 40 new products; adventure comedy Thomas Edison's Secret Lab®, available on Netflix, public broadcast stations and GBI's Kid Genius channel on Comcast's Xfinity on Demand; Warren Buffett's Secret Millionaires Club, created with and starring iconic investor Warren Buffett. The company is also co-producing an all-new adult animated series, Stan Lee's Cosmic Crusaders, with Stan Lee's Pow! Entertainment and The Hollywood Reporter. Additionally, under GBI's wholly owned subsidiary, A Squared Entertainment, the company represents third-party properties, including From Frank, a humor greeting card and product line, and Celessence Technologies, the world's leading micro encapsulation company, across a broad range of categories in territories around the world. For additional information please visit www.gnusbrands.com.

About HeR Interactive:
Based in Bellevue, Washington, HeR Interactive was a pioneer in 1998 when it began developing and publishing Nancy Drew interactive games for females. Since then, the company has released over 32 games, won 30 Parents' Choice awards and has sold more than 9 million copies of its games. Nancy Drew players now include moms who have introduced their daughters to the girl detective, making her one of history's longest-running iconic figures spanning generations. More information about the company and Nancy Drew games can be found at www.herinteractive.com.

About Nancy Drew:
Nancy Drew debuted in 1930 and is still going strong. She is a smart, independent, gutsy and resourceful teen detective who can crack even the toughest case. Published in 22 languages and with more than 100 million copies in print worldwide, Nancy Drew has engaged readers and served as a role model globally for generations. NANCY DREW is a registered trademark of Simon & Schuster, Inc. Licensed by permission of Simon & Schuster, Inc.

Genius Brands International Closes $5.2 Million Credit Facility With Bank Leumi

 Source:  Genius Brands International, Inc.


Genius Brands International "GBI" (OTCQB: GNUS) announces today the close of a $5.2million credit facility with Bank Leumi secured by its Netflix agreement to produce 30 x 11' episodes of Llama Llama, a new animated preschool series starring the voice talent of Jennifer Garner, based on the New York Times #1 bestselling children's book franchise.

"This is a milestone agreement for GBI on many levels," commented Andy Heyward, Chairman & CEO, GBI. "Since we sold neither stock nor equity, there is no dilution for this money. It insures we will have access to the value of the Netflix contract (which is payable on and in the months after delivery), and we will have no need for raising funds to produce the series. It also speaks to 3rd party validation of GBI's creditworthiness, by an active and well respected lender in the entertainment credit community."

GBI filed an 8K with the SEC on Friday, August 12, 2016 announcing the facility.

About Genius Brands International
Headquartered in Beverly Hills, California, Genius Brands International, Inc. "GBI" (OTCQB: GNUS) is a publicly traded global brand management company that creates and licenses multimedia content. Led by award-winning creators and producers, the company distributes its content worldwide in all formats, as well as a broad range of consumer products based on its characters. In the children's media sector, GBI's portfolio features "content with a purpose" for toddlers to tweens, which provides enrichment as well as entertainment, including tween music-driven brand SpacePOP; preschool property debuting on Netflix Llama Llama; award-winning Baby Genius, re-launched with new entertainment and over 40 new products; adventure comedy Thomas Edison's Secret Lab®, available on Netflix, public broadcast stations and GBI's Kid Genius channel on Comcast's Xfinity on Demand; Warren Buffett's Secret Millionaires Club, created with and starring iconic investor Warren Buffett. The company is also co-producing an all-new adult animated series, Cosmic Crusaders, with Stan Lee's Pow! Entertainment and The Hollywood Reporter. Additionally under GBI's wholly owned subsidiary, A Squared Entertainment, the company represents third-party properties, including From Frank, a humor greeting card and product line, and Celessence Technologies, the world's leading micro encapsulation company, across a broad range of categories in territories around the world. For additional information please visit www.gnusbrands.com.

Spotlight Innovation Enters into Sponsored Research Agreement with Florida State University to Support Prof. Hengli Tang in the Development of Treatments for Zika Virus Infection

Source:  Spotlight Innovation, Inc.

Spotlight Innovation Inc. (OTCQB: STLT) has entered into a Sponsored Research Agreement with Florida State University (FSU) to support research directed by FSU Prof. Hengli Tang aimed at developing safe and effective drugs to treat patients infected with Zika virus (ZIKV).

Prof. Tang is an accomplished virologist whose research has been published in prominent academic journals including Cell and Journal of Virology. In March 2016, Prof. Tang co-authored a study¹ published in Cell Stem Cell that demonstrated for the first time the ability of ZIKV to target human embryonic cortical neural progenitor cells. After infecting these crucial brain development cells, the virus replicates and interferes with cell growth, function and viability. ZIKV infection in pregnant women can cause neurological birth defects, including microcephaly, a condition in which a child is born with an abnormally small head as a result of incomplete brain development.

Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development, commented, "Prof. Tang is a true pioneer in the scientific community's efforts to combat Zika virus. We are thrilled that he has chosen to collaborate with us to develop novel therapies for Zika virus infection."

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Spotlight Innovation Launches Development of STL-182 to Treat Spinal Muscular Atrophy

Source:  Spotlight Innovation, Inc.

Spotlight Innovation Inc. (OTCQB: STLT) today announced that it has obtained an exclusive, worldwide license from Indiana University Research and Technology Corp. to commercialize STL-182, an orally-available small molecule that may have therapeutic potential for treating Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is a leading genetic cause of death in infants and toddlers. Synthesis and early preclinical testing of STL-182 was accomplished through a research collaboration between Professors Elliot Androphy of Indiana University School of Medicine and Kevin Hodgetts, director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women's Hospital. Their work was supported in part by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Child Health and Human Development (NICHD).

Spinal Muscular Atrophy affects between 1 in 6,000 and 1 in 10,000 newborns. Approximately 1 in 40 to 1 in 50 adults have only a single intact spinal motor neuron 1 (SMN1) gene, which encodes a protein (SMN) required for proper neuromuscular function. An infant who inherits no intact SMN1 gene from either parent may develop SMA and lose the ability to sit, stand, walk, swallow, and/or breathe. In about 60% of cases, patients with SMA die by age two.

Even in SMA patients, low levels of functional SMN protein are produced by an SMN1-related gene called SMN2. One therapeutic strategy to treat SMA is to increase levels of functional SMN protein encoded by SMN2. In mouse models of SMA, STL-182 may restore neuromuscular function by stabilizing endogenous SMN protein.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Spotlight Innovation's Newly Established Subsidiary Caretta Therapeutics Enters into Exclusive Licensing Agreement to Develop and Commercialize Analgesic Products

Source:  Spotlight Innovation, Inc.

Spotlight Innovation Inc. (OTCQB: STLT) today announced that it has established subsidiary Caretta Therapeutics, and that the subsidiary has entered into a licensing agreement with Dr. Paul Reid for rights to develop and commercialize products derived from snake venom that may provide analgesic relief from moderate to severe chronic pain. Under the terms of the agreement, Dr. Reid has agreed to grant an exclusive, worldwide license to Caretta Therapeutics to develop, manufacture and sell the products.

Caretta Therapeutics intends to begin manufacturing its first products by late 2016 and to begin commercial distribution of over-the-counter formulations beginning in 2017.

The National Institutes of Health's National Center for Complementary and Integrative Health, utilizing data from the 2012 National Health Interview Survey, estimates that nearly 50 million American adults have significant chronic pain or severe pain.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Spotlight Innovation Research Collaborator Prof. Hengli Tang Publishes Landmark Study in Nature Medicine

Source:  Spotlight Innovation, Inc.

Drug Repurposing Screen Identifies Lead Compounds for Anti-Zika Virus Drug Development

Spotlight Innovation Inc. (OTCQB: STLT) announced today that Prof. Hengli Tang has co-authored a study¹, published in Nature Medicine on August 29, 2016, reporting two classes of compounds: one that protects Zika virus-infected neural cells from programmed cell death ("apoptosis") and another that directly inhibits Zika virus replication. According to the study, when used in combination, compounds from the two classes enhanced the neuroprotective effect.

Since the resurgence of Zika over a year ago, efforts to combat the virus have focused largely on preventing infection through vaccine development, mosquito control measures and public health education. The availability of anti-Zika therapeutics could provide physicians with tools to treat patients who have already been infected. Funding provided by Spotlight Innovation under a Sponsored Research Agreement with Florida State University will enable Prof. Tang and his collaborators to expand on their discoveries and to accelerate the development of safe and effective drugs to treat patients infected with Zika.

Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development, commented, "Prof. Tang's important work reinforces our long-standing conviction that he and his collaborators will significantly advance the field of anti-Zika virus drug development."

In a recent publication², Prof. Tang and his collaborators demonstrated that Zika virus can infect and replicate within human embryonic cortical neural progenitor cells. Zika infection in pregnant women can cause neurological birth defects, including microcephaly, a condition in which a child is born with an abnormally small head as a result of incomplete brain development.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

¹ Miao X, Lee EM, Wen Z, Cheng Y, Huang W-K, Qian X, TCW J, Kouznetsova J, Ogden SC, Hammack C, Nguyen HN, Itkin M, Hanna C, Shinn P, Allen C, Michael SG, Simeonov A, Huang W, Christian KM, Goate A, Brennand K, Huang R, Menghang X, Ming G-L, Zheng W, Song H, Tang H. Identification of Small Molecule Inhibitors of Zika Virus Infection and Induced Neural Cell Death Via a Drug Repurposing Screen. Nature Med. 2016 Aug 29. 
http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4184.html

² Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, Yao B, Shin J, Zhang F, Lee EM, Christian KM, Didier RA, Jin P, Song H, Ming GL.  Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth. Cell Stem Cell. 2016 Mar 3. pii: S1934-5909(16)00106-5. doi: 10.1016/j.stem.2016.02.016. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/26952870

Spotlight Innovation Announces Debt Restructuring Through Conversion of $850,000 in Convertible Promissory Notes

Source:  Spotlight Innovation, Inc.

Spotlight Innovation Inc. (OTCQB: STLT) announced today that the holders of a series of convertible promissory notes issued between December 2015 and March 2016, totaling $850,000, have agreed to convert the promissory notes into shares of Common Stock.

"This conversion is a positive step toward simplifying our balance sheet," said Mr. Cristopher Grunewald, Spotlight Innovation's President and Chief Executive Officer. "Debt restructuring allows us to accelerate development of our product candidates, creating value for both current and future shareholders. Moving forward, we will continue to look for debt restructuring opportunities that further our development goals."

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Source:  Medovex Corp.

Medovex Corporation Begins Commercial Production of DenerveX™ Pro-40 Generator in Preparation for EU Launch 

Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that it and its design and manufacturing partner Bovie Medical have commenced commercial production of the Company's DenerveX™ Pro-40 Power Generator as one more step towards the launch in the EU. Bovie Medical is a Florida based world leader in the development and manufacture of electrosurgical products.

"Bovie is a highly respected leader in this field," said Jarrett Gorlin, Chief Executive Officer of Medovex Corporation. "We are very pleased to nearing the completion of the design and testing stage, now moving to commercial production. Working with Bovie Medical has ensured that the power source to the DenerveX Device, focused on treatment of patients with Facet Joint Pain, will be safely and effectively matched with the device itself." The DenerveX Power generator Pro-40 was specifically designed and manufactured as a dedicated power generator for the Company's DenerveX Device.

According to Patrick Kullmann, President and COO, "The DenerveX Pro-40 generator will offer the optimal power source to the single use DenerveX device without relying on other less reliably matched power sources in the market today. The DenerveX system consists of the DenerveX Pro-40 generator and the DenerveX device. The combined system results in an exclusively matched system that will serve our customers and their patients well in the areas of quality of therapy delivery and safety. The DenerveX Pro-40 will provide both RF energy and motor power to the DenerveX device for the treatment of Facet Joint Syndrome, a very common and problematic source of back pain."

The Company's patented DenerveX System, currently in the final development stages and not yet commercially available, is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device kit, a single use device, and the reusable DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system.

DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

 

Source:  Medovex Corp.

Medovex Corp. Completes Financing Led by Sorrento Therapeutics, Inc.

Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced the successful completion of a $1,150,000 financing transaction led by an investment from Sorrento Therapeutics, Inc. (NASDAQ: SRNE).

On August 5, 2016, MedoveX Corporation entered into a unit purchase agreement with selected accredited investors. Pursuant to the terms of the agreement, the Company sold 4.6 units for gross proceeds of $1,150,000. Each unit had a purchase price of $250,000 and consists of 208,333 shares of the Company's common stock, and a warrant to purchase 104,167 shares of common stock. Each warrant has an initial exercise price of $1.52 per share, subject to adjustment, and is initially exercisable six months following the date of issuance for a period of five years from the date of issuance.

Sorrento Therapeutics, Inc. acted as the lead investor contributing $750,000.

Jarrett Gorlin, Medovex Corporation Chief Executive Officer, stated, "We are clearly pleased to have closed this financing led by Sorrento Therapeutics. We believe their sizeable investment is indicative of a shared optimism regarding the potential for the development and future commercialization of the DenerveX™ System. We continue to work aggressively towards a future CE mark process and successful launch in the European Union and other countries that accept the CE mark globally."

Gorlin continued, "Recent test results found that the DenerveX kit and generator successfully worked together in an excellent manner, as designed and developed at this stage of development. The successful tests pave the way towards the completion of the final set of testing and verification. The system used in this laboratory testing consisted of the latest pre-production model of the system that is the identical model to the device for human use. It represents a continued confirmation of the future utility of the DenerveX System in treating patients with Facet Joint Syndrome."

Additional details of the financing may be found in the Form 8K filed with the Securities and Exchange Commission on August 8, 2016.

The Company's patented DenerveX System, currently in the final development stages and not yet commercially available, is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device kit, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system.

DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Source:  Medovex Corp.

Medovex Corporation Reports Successful Demonstration of Expanding EMEA Business at EuroSpine 2016, Berlin, Germany

Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the Company successfully exhibited its' DenerveX™ System during EuroSpine 2016 Tradeshow last week in Berlin, Germany.

As part of the product exhibition, Medovex highlighted its innovative DenerveX™ System, a minimally invasive surgical (MIS) procedure pioneered by Medovex that was built around the denervation of the posterior capsulectomy of the Facet Joint using our patented Rotablation™ technology which is "A significant paradigm shift in the treatment of Facet Joint pain."

Patrick Kullmann, President and COO for Medovex, stated, "We consider EuroSpine 2016 in Berlin our 'pre-launch' meeting leading up to what is expected to be an eventual formal CE Marking. In particular, we were very pleased to see visiting surgeons and distributors from more than 25 countries, and from all continents, at our booth, along with existing and new potential distributors visiting with us."

Kullmann continued, "Importantly, we conducted meetings and demonstrations with at least six potentially strategic companies that could open the door to future collaboration for distribution, investment, co-future development of future generations of the technology or even potential acquisition. Many of the spine surgeons and pain relief physicians visiting the booth stated that the DenerveX Design is very elegant, and represents a very new and creative approach in treating pain associated with the Facet Joint Syndrome. Their clear appreciation for our different approach in performing a new procedure by way of a posterior capsulectomy of the facet joint, compared to the less effective standard radio frequency ablation (Rhizotomy), gives us cause for continued cautious optimism going forward."

During EuroSpine 2016, Medovex also announced the official opening of the Company's European Distribution Center in Berlin.

The Center will serve as Medovex's European distribution service headquarters and function as the commercial hub for all European distributors, as well as other customer and technical support functions. The international operations center in Atlanta, GA (USA) will remain the Company's global operational headquarters.

Manfred Sablowski, Senior Vice President of Global Sales & Marketing, added, "The opening of the European distribution service center is an important milestone for Medovex and a key inflection point for our Company's strategy to grow our business in Europe, Middle Eastern and Africa regions. In the past months, we have additionally expanded our footprint to include all of Scandinavia and Israel. Our future goal is to increase our world-class EMEA distribution in other key countries. With the recent appointment of Juan Davila as Director Sales & Marketing for Latin America, having extensive experience in this market, we expect to continue to execute our go to market strategy."

The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator, both designed to be less invasive with faster recovery time than current surgical treatment options. It consists of two procedures combined into one device and is expected to provide for a longer lasting treatment solution while offering potential savings to the health care system. DenerveX is not yet commercially available.

DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

 

 

Medovex Corporation Enters Into International Distribution Agreement With M.Fast Technologies LTD

Source:  Medovex Corp.

Leading Supplier of Innovative Spine Surgery Products to Distribute the DenerveX™ System Throughout Israel

Medovex Corp. (NASDAQ: MDVX) ("Medovex" or "Company"), a developer of medical technology products, today announced that the Company has entered into an international distribution agreement with M.Fast Technologies LTD, a supplier of innovative Spine surgery products. The agreement covers the distribution of its DenerveX™ System throughout Israel.

Dennis Moon, Medovex Executive Vice President, stated, "M.Fast Technologies LTD serves as a perfect call point fit for our mission to provide a successful distribution, sales and marketing foundation for our entry of the DenerveX System in the Middle East."

"With M.Fast Technologies LTD as a specialized distributor offering complex and innovative spine products throughout Israel, we are closing a gap while showing a professional presence in a major market," added Manfred Sablowski, Senior Vice President Sales & Marketing. "Today's news importantly enables Medovex to expand the use of the DenerveX System into the Middle East, where M.Fast Technologies is a well established successful distributor. We expect the agreement will help in our efforts to increase worldwide adoption of the DenerveX System."

Sablowski continued, "Our goal remains to continuously improve our international market presence by expanding our network of strong distributors with knowledgeable sales and support personnel, and in close proximity to our customers."

Medovex already has distribution agreements for the DenerveX System in Germany, Spain, UK, Denmark, Norway, Sweden, Finland in Europe and Asia Pacific, as well as in select other countries around the world.

The Company's patented DenerveX System, currently in final development and not yet commercially available, is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device kit containing a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX System is designed to provide a minimally invasive treatment option which combines two actions into one device.

DenerveX is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com.

Medovex Corporation Expands Launch Plan With Latin American Management Hire

Source:  Medovex Corp.

Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the Company has hired Mr. Juan Davila as Director Sales & Marketing for their DenerveX™ division of the business.

Mr. Davila, a Sales & Marketing leader with more than over 20 years of experience in the Latin-American Market, is recognized for his excellent record of business growth and market development of new products in the highly competitive medical devices industry in Latin America. Mr. Davila has a strong marketing and communication skills, in both Spanish and Portuguese.

Davila will be developing and implementing an overall corporate sales, marketing and strategy, directly engaging and managing all future Medovex Distributors throughout the Americas, and translating the company's business objectives into marketing strategies that drive future revenue. In addition, Mr. Davila will also provide services to help introduce the Medovex's DenerveX™ System to leading physicians and medical professionals in Latin America.

"Juan drives market awareness and qualified sales leads through a rare combination of medical technology savvy, customer, distributor focus and persuasive communication," said Manfred Sablowski, Medovex Senior Vice President Global Sales & Marketing. "His skill set spans all aspects of Sales & Marketing, and we are thrilled to be adding such a deep talent to the Medovex team."
Sablowski continues, "Juan Davila fits our mission to provide a world-wide distribution channel for our DenerveX System, while serving an important market segment in Latin America."

Prior to accepting this position, Davila established successful his own consulting firm with focus on the Latin American Healthcare Market and worked for Worldwide well known Medical Technology Companies like Valleylab (former Tyco/U.S Surgical/Pfizer) as General Manager Latin America which resulted in sales growth of 850% as well as Howmedica (former Pfizer).

The Company's patented DenerveX™ System is intended to treat Facet Joint Syndrome (FJS), a condition in which the joints in the back of the spine degenerate and subsequently cause pain. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to FJS pain.

The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator, both designed to be less invasive with faster recovery time than current surgical treatment options. It consists of two procedures combined into one device and is expected to provide for a longer lasting treatment solution while offering potential savings to the health care system. DenerveX is not yet commercially available.

DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Medovex Corporation Adds 35 Year Orthopedic Industry Veteran Ron Lawson to Board of Directors

Source:  Medovex Corp.

Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, announced today that it has added orthopedic industry veteran Ron Lawson to its Board of Directors.

Ron Lawson's 35 plus years of experience in the orthopedic industry include the role as Senior Vice President of Worldwide Sales and Customer Service for Pfizer's Orthopedic Division, Howmedica (1996). In 1998, he became part of the Stryker Corporation with Stryker's acquisition of Howmedica. At Stryker, he served as Senior Vice President of Sales, Marketing and Product Development. Mr. Lawson also played a critical and insightful role in the successful integration of the two companies. In 2000, he was asked to lead the revitalization of Stryker's European business as President, EMEA. He shortly thereafter assumed the role of leadership for all of Stryker's International distribution businesses and was promoted to Group President, International in 2001.

In 2005, Stryker assigned global responsibility of their orthopedic division to Mr. Lawson making him Group President for International and Global Orthopedics. He then focused on strengthening the Stryker Orthopedic business worldwide. Ron retired from Stryker at the end of 2007.

Ron Lawson is currently a member of the Lawson Group where he provides strategic consulting services specializing in orthopedic medical technology. He previously served as Chairman of the Board of IMDS, Corporation. He also served as a member of the Health Care Advisory Board of Arsenal Capital Partners. He presently serves as a Director of Plasmology 4, Corporation as well as a Director of DJO Global, a Blackstone company.

Jarrett Gorlin, Medovex Corporation Chief Executive Officer, stated, "Mr. Lawson is well regarded as one of the key leaders aided in the development of the orthopedic industry. With the progress of our flagship DenerveX™ Device and other opportunities currently under review, his addition to our team is highly strategic. We look forward to working with Ron and leveraging his relationships throughout the world. I'd also like to say a special thank you to outgoing board member Thomas Hills for all of his invaluable support over the last couple years."

Ron Lawson added, "I am pleased to have the opportunity to serve on the Board of Medovex Corporation at a time I believe to be an inflection point for the Company. The company is now strategically positioned to offer great value to both surgeons and patients dealing with pain associated with the Facet Joint. I look forward to assisting management in identifying and vetting other potentially complementary additions to its portfolio of assets, as well as helping to further strengthen the Company's relationships with surgeon opinion leaders around the world."

The Company's patented DenerveX System is currently in the final development stages. It is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and 31% of those affected are attributed to facet joint pain.

The DenerveX System consists of the DenerveX device kit, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system.

DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com